jcp conference-coverage

Conference Coverage

Real-World Utilization of Second-Line Maintenance Therapy for Patients With Ovarian Cancer

06/07/2021

Fewer than half of eligible patients with advanced ovarian cancer receive second-line maintenance therapy, according to results from a real-world analysis.

Fewer than half of eligible...

06/07/2021

Journal of Clinical Pathways

Conference Coverage

Treatment Patterns Following First-Line Therapy for HER2-Positive Metastatic Breast Cancer

06/07/2021

A study exploring practice patterns in HER2-positive breast cancer in the United States found that the most common second-line treatment following first-line pertuzumab plus trastuzumab were T-DM1-based regimens.

A study exploring practice...

06/07/2021

Journal of Clinical Pathways

Conference Coverage

Real-World Outcomes of Patients Receiving Alpelisib for PIK3CA-Mutated Breast Cancer

06/07/2021

Patients with breast cancer and PIK3CA mutations who receive alpelisib plus fulvestrant have longer real-world PFS compared with those who receive fulvestrant alone.

Patients with breast cancer and...

06/07/2021

Journal of Clinical Pathways

Conference Coverage

Cost-Effectiveness of Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for Early Breast Cancer

06/07/2021

Neoadjuvant pertuzumab, trastuzumab, and hyaluronidase-zzxf plus chemotherapy is expected to be cost-effective vs neoadjuvant pertuzumab and trastuzumab plus chemotherapy for patients with high-risk HER2-positive early breast cancer.

Neoadjuvant pertuzumab,...

06/07/2021

Journal of Clinical Pathways

Conference Coverage

Cost-Effectiveness of Adjuvant Osimertinib vs Placebo in NSCLC

06/02/2021

Study findings suggest adjuvant osimertinib is more cost-effective than placebo if one is willing to pay $317,119 more per QALY gained.

Study findings suggest adjuvant...

06/02/2021

Journal of Clinical Pathways

Conference Coverage

Cost-Effectiveness of Temozolomide Use in Patients with Glioblastoma

06/02/2021

Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.

Study findings support...

06/02/2021

Journal of Clinical Pathways

Conference Coverage

Recent Advancements in Biomarker Testing and Therapeutic Strategies in Oncology

05/03/2021

Journal of Clinical Pathways

Conference Coverage

Ensuring Quality on the Path to Cancer Care Reform

05/03/2021

Journal of Clinical Pathways

Conference Coverage

Integrating Palliative Care Into Community Oncology Practice

04/29/2021

Journal of Clinical Pathways

Conference Coverage

Defining Value in Cancer Care

04/29/2021

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products